



SDAI Limited
(Company Registration No. 201107179D)
(Incorporated in the Republic of Singapore on 25 March 2011)

FOR IMMEDIATE RELEASE

SDAI to Launch its Proprietary Plant Stem Cells Skincare in Singapore and China as Part of Strategic Transformation into a Biotechnology Company

- The milestone launch will mark a significant step in the Group's transformation journey and reinforce commitment to long-term growth
- The Biotech B-III skincare series is designed to harness the regenerative properties of nature by focusing on cellular rejuvenation
- Aims to establish itself as a leader in biotechnology through its breakthrough work in cellular rejuvenation

SINGAPORE, 10 December 2025 – The board of directors (the “**Board**”) of SDAI Limited (the “**Company**” or “**SDAI**”, and together with its subsidiaries, the “**Group**”) is pleased to announce that the official launch of its proprietary skincare line, **Bluecode Biotech B-III skincare series (蓝码生物 B-III 系列)** (“**B-III Series**”) will take place on 21 December 2025, marking a pivotal milestone in SDAI's transformation journey as it expands the Group's business into high-growth anti-aging and biotechnology sectors.

The B-III Series is scheduled to debut simultaneously in Singapore and China, with Singapore's first product being the Photoprotective Bio Facial Mist (抗光损喷雾), while the China market will see the concurrent launch of three products: (i) the Apple Fruit Cell Serum (苹果果实细胞精华液), (ii) the Photoprotective Bio Facial Mist and (iii) the Adenium Obesum Cell Facial Mask (沙漠蔷薇叶细胞面膜). The new products will be distributed primarily through established e-commerce platforms to maximise market reach and consumer accessibility.

Plant stem cell based skincare products leveraging advanced technology

The Group has developed the B-III Series through its in-house research and development capabilities. The Bluecode Biotech B-III brand is positioned to redefine skincare by introducing an innovative approach that restores cell-to-cell communication to activate the skin's natural self-repair power (激发肌肤细胞自愈力). Leveraging cutting-edge third-generation bioengineering and plant stem-cell technologies, the B-III Series addresses factors associated with cellular aging.



SDAI Limited
(Company Registration No. 201107179D)
(Incorporated in the Republic of Singapore on 25 March 2011)

The B-III Series currently comprises three plant stem cell–based skincare products:

(i) **Apple Fruit Cell Serum**



The Apple Fruit Cell Serum¹ contains extracts derived from Uttwiler Spätlauber apple stem cells sourced from a Swiss apple variety known for its regenerative qualities to activate the skins' natural self-repair ability.

(ii) **Anti-Photoprotective Bio Facial Mist**



The Anti-Photoprotective Bio Facial Mist, which is formulated using light-filtering and barrier-support technologies, is designed for topical application without the use of conventional sunscreen active ingredients.

¹ Uttwiler Spätlauber apple stem cells, <https://www.swissinfo.ch/eng/banking-fintech/a-swiss-apple-a-day-keeps-wrinkles-at-bay/7668056>



SDAI Limited
(Company Registration No. 201107179D)
(Incorporated in the Republic of Singapore on 25 March 2011)

(iii) **Adenium Obesum Cell Facial Mask**



The Adenium Obesum Cell Facial Mask, which incorporates nano-emulsion delivery technology, contains highland gentian root extract, ectoine and ergothioneine to soothe, restore and strengthen photodamaged skins.

These new products have been developed as part of the Group's product portfolio diversification strategy.

For more information about the new products, please refer to the "News & Press Releases" page on the Company's corporate website.

Madam Hao Dongting (郝东亭), Executive Chairperson of the Company, commented, "Our transformation journey is progressively yielding results. The successful launch of the Bluecode Biotech B-III skincare series in both the Singapore and China markets is expected to represent a significant milestone in our ongoing transformation, symbolising both progress and promise. This launch represents the Group's first step toward delivering innovative health and wellness solutions to consumers and reflects the management team's unwavering determination and capability to create sustainable value for shareholders of the Company.

The biotechnology industry offers vast and promising growth opportunities. The Group's strategy to enter into this sector is intended to enable the Group to access its immense potential, diversify its revenue streams and strengthen its long-term growth prospects. The Group remains steadfast in its commitment to maximising shareholder value and aims to establish itself as a leading player in biotechnology through breakthrough advancements in cellular rejuvenation."

- END -



SDAI Limited
(Company Registration No. 201107179D)
(Incorporated in the Republic of Singapore on 25 March 2011)

About SDAI Limited

Listed on the Catalist Board of the Singapore Exchange since July 2011, SDAI Limited ("**SDAI**", and together with its subsidiaries, the "**Group**") is undergoing a strategic transformation into a biotechnology company specialising in healthcare-related products and services.

As the first step in this biotechnology-driven transformation, the Group has launched the Bluecode Biotech B-III skincare series, an advanced line of plant stem cell skincare products.

The Group plans to integrate biotechnology across the medical, skincare, and health products industries and is committed to become a leading force in the biotechnology space.

For more information, please visit www.sdai.com.sg

Issued for and on behalf of SDAI Limited by Woodnote Consulting

Yong Jing Wen

E: jingwen@woodnoteconsulting.com

T: (65) 9860 3047

*This press release has been reviewed by the Company's sponsor, ZICO Capital Pte. Ltd. (the "**Sponsor**").*

*This press release has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "**SGX-ST**") and the SGX-ST assumes no responsibility for the contents of this press release, including the correctness of any of the statements or opinions made or reports contained in this press release.*

The contact person for the Sponsor is Ms Yang Zhenni, ZICO Capital Pte. Ltd. at 77 Robinson Road, #06-03 Robinson 77, Singapore 068896, telephone (65) 6636 4201.